Genomes and Genes


W A Schulz


Affiliation: Heinrich Heine University
Country: Germany


  1. Schulz W, Hoffmann M. Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol. 2009;19:172-80 pubmed publisher
    ..Because of their crucial role, epigenetic alterations may become highly useful for diagnostics and therapy of prostate cancer. ..
  2. Lang A, Yilmaz M, Hader C, Murday S, Kunz X, Wagner N, et al. Contingencies of UTX/KDM6A Action in Urothelial Carcinoma. Cancers (Basel). 2019;11: pubmed publisher
    ..In particular, we provide evidence that these factors determine the amount of nuclear UTX. ..
  3. Kaletsch A, Pinkerneil M, Hoffmann M, Jaguva Vasudevan A, Wang C, Hansen F, et al. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Clin Epigenetics. 2018;10:100 pubmed publisher
    ..Our results suggest that targeting of class IIA HDACs 4/5 may not be optimal for UC therapy. Moreover, our investigation provides further evidence for cross-regulation of class IIA HDACs by class I HDACs. ..
  4. Schulz W, Koutsogiannouli E, Niegisch G, Hoffmann M. Epigenetics of urothelial carcinoma. Methods Mol Biol. 2015;1238:183-215 pubmed publisher
    ..There are indeed excellent biomarker candidates for DNA-methylation-based diagnostics of urothelial carcinoma, whereas miRNAs are well investigated, but there are still many discrepancies between studies published to date. ..
  5. Greife A, Hoffmann M, Schulz W. Consequences of Disrupted Notch Signaling in Bladder Cancer. Eur Urol. 2015;68:3-4 pubmed publisher
    ..Especially in invasive urothelial carcinoma, the pathway is inactivated instead, and drugs inhibiting Notch signaling are likely contra-indicated. ..
  6. Pixberg C, Schulz W, Stoecklein N, Neves R. Characterization of DNA Methylation in Circulating Tumor Cells. Genes (Basel). 2015;6:1053-75 pubmed publisher
    ..As recent studies have started to address the epigenetic state of CTCs, we discuss here the potential of such investigations to elucidate mechanisms of metastasis and to develop tumor biomarkers. ..
  7. Earl J, Rico D, Carrillo de Santa Pau E, Rodríguez Santiago B, Méndez Pertuz M, Auer H, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics. 2015;16:403 pubmed publisher
  8. Earl J, Rico D, Carrillo de Santa Pau E, Rodríguez Santiago B, Méndez Pertuz M, Auer H, et al. Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies. BMC Genomics. 2015;16:1019 pubmed publisher
  9. Schulz W, Ingenwerth M, Djuidje C, Hader C, Rahnenführer J, Engers R. Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer. 2010;10:505 pubmed publisher
    ..We hypothesize that these alterations may contribute to the increased invasivity conferred to prostate cancer cells by ERG deregulation. ..

More Information


  1. Isono M, Hoffmann M, Pinkerneil M, Sato A, Michaelis M, Cinatl J, et al. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. J Exp Clin Cancer Res. 2017;36:1 pubmed publisher
    ..AZD7762 enhanced sensitivity of urothelial carcinoma cells to gemcitabine by inhibiting DNA repair and disturbing checkpoints. Combining gemcitabine with CHK1 inhibition holds promise for urothelial cancer therapy. ..